Mobile Menu

Pharma data as an asset: how to become information centric

Whilst the life sciences and biopharmaceutical industries are moving to a more data driven approach in their research, data is not always treated as a valuable asset. Rather, the levels of investment in data curation do not match the value that reusable data will bring across the R&D value chain. Without access to clean, reusable data to train machine algorithms we will not be able to leverage their full potential for biopharma research.

Through several Innovative Medicines Initiative (IMI) projects it was established that harnessing principles to make datasets Findable, Accessible, Interoperable and Reusable would become a priority undertaking for the pharmaceutical industry to allow for the full exploitation of these transformative technologies.

In a recent webinar, Dr Martin Romacker, Principal Scientist, Data and Information Architecture at Roche, takes us through the FAIR data principles and how access to clean reusable data will drive value across the R&D value chain.

Click here to access the webinar

If you would like to learn more about the practical implementation of the FAIR principles, from several leading biopharma organisations, we have the webinar series for you. Catch up OnDemand here to hear the lessons learned and benchmark how you can improve FAIRification programmes in your organisation.

Share this article